33
Advanced33Pharmacology33for33Prescribers331st33Edition33Luu33Kayingo33LatestE
d33ition,332024
, Table of Contents
33 33
Chapter331:33An33Introduction33to33Evidence-Based33Clinical33Practice33Guidelines......................................... 3
Chapter332:33Pharmacokinetics33/Chapter3:33Pharmacodynamics .................................................................. 13
Chapter4:33Pharmacogenetics33and33Pharmacogenomics .............................................................................. 25
Chapter335:33Pharmacology33Across33the33Life33Span ..................................................................................... 30
Chapter336:33Drug-Therapy33Prescribing33insSpecial33Populations ................................................................. 36
Chapter337:33Drug33Developmentsand33Approval ........................................................................................... 45
Chapter338-Chapter3310:33Foundations33of33PrescriptionsWriting33Chapter339:33ResponsibleControlled-
33SubstancePrescribing33Chapter33 10:33AntibioticsStewardship ..................................................................... 51
Chapter3311:33Applied33Calculations33for33Prescribing................................................................................... 58
Chapter33 12-:33Promoting33Adherence33WithsPharmacotherapy33II:33System-Specific33and33Patient-
Focused33Prescribing33Chapter3313:33Pharmacotherapy33for33Ear,33Nose,33Mouth,33andThroat33Conditions33/C
hapters1334:33Pharmacotherapy33for33Eye33Conditions .................................................................................... 67
Chapter3315:33Pharmacotherapy33for33Skin33Conditions ................................................................................. 74
Chapter3316:33Pharmacotherapy33for33Neurologic33Conditions ...................................................................... 81
Chapter3317:33Pharmacotherapy33for33Cardiovascular33Conditions ................................................................ 94
Chapter3318:33Pharmacotherapy33for33Respiratory33Conditions.................................................................... 106
Chapter3319:33Pharmacotherapy33for33Gastrointestinal33Conditions33and33Conditions33RequiringNutritional33S
uppor33t ...................................................................................................................................................... 117
Chapter3320:33Pharmacotherapy33for33Genitourinary33Conditions ................................................................ 128
Chapter3321:33Pharmacotherapy33for33Renal,33Acid–Base,33Fluid,33and33Electrolyte33Disorders .................... 133
Chapter3322:33Pharmacotherapy33for33Musculoskeletal33and33Rheumatologic33Conditions .......................... 146
Chapter3323:33Therapeutic33Applications33of33Immunology33and33Vaccines ................................................ 158
Chapter3324:33Pharmacotherapy33for33Endocrine33Disorders ........................................................................ 163
Chapter3325:33Pharmacotherapy33for33Hematologic33Disorders .................................................................... 174
Chapter3326:33Hematology/Oncology33and33Supportive33Care33for33the33Nononcologist ............................... 190
Chapter33 27:33Pharmacotherapy33Related33tosWomen’s33Health33Conditions............................................... 196
Chapter3328:33Pharmacotherapy33Related33to33Men’s33Health33Conditions.................................................... 211
Chapter3329:33Pharmacotherapy33Related33to33Transgender33Care ............................................................... 217
Chapter3330:33Antimicrobial33Pharmacotherapy .......................................................................................... 224
Chapter3331:33Antiretroviral33Pharmacotherapy .......................................................................................... 235
Chapter3332:33Psychopharmacology33and33Integrative33Health:33Combined33Treatment33ofPsychiatric33and33Neu
rocog33nitive33Conditions ............................................................................................................................ 247
Chapter3333:33Pharmacotherapy33for33Pain33Management ............................................................................ 257
Chapter3334:33SubstancesUse33Disorder33III:33Health33Promotion33and33Maintenance.................................... 267
Chapter3335:33Over-the-Counter33Medications ............................................................................................ 283
Chapter3336:33Pharmacotherapy33for33Obesity ............................................................................................. 291
,Chapter331:33An33Introduction33to33Evidence-Based33Clinical33Practice33Guidelines
MULTIPLE33CHOICE
• What33is33the33primary33purposesof33the33nursing33assessment?
A. Identifying33underlying33pathologic33conditions
B. Assisting33the33physician33in33identifying33medical33conditions
C. Determining33the33patients33mental33status
D. Exploring33patient33responses33to33health33problems
ANS:33D
Anursing33assessment33is33done33to33identify33the33patients33response33to33health
33probl33ems.33During33thesnursingsassessment33phase,33a33comprehensive33infor
mationsbas33e33is33developed33through33a33physical33examination,33nursing33histo
ry,33medication33h33istory,33and33professional33observation.33Identifying33underl
ying33pathologic33cond33itions33and33assisting33the33physician33in33identifyingm
edical33conditions33is33not33part33ofsthe33nursing33process.33Determining33the33pat
ients33mental33statuss33is33one33part33of33t33he33nursing33assessment,33but33it33is33n
otsthesprimary33purpose.
DIF:33Cognitive33Level:33Comprehensi
on33REF:33dm333633OBJ:33133|33333TOP:33N
ursing33Pr33ocess33Step:33Assessment
MSC:33NCLEX33Client33Needs33Category:33Health33Promotion33and33Maintenance
• What33issthe33basis33of33the33NANDA33I33taxonomy?
A. Functional33health33patterns
B. Human33response33patterns
C. Basic33human33needs
D. Pathophysiologic33needs
ANS:33B
The33NANDA33I33taxonomy3 3 identifies3 3 humans3 3 response3 3 patterns.33Funct
ional33components33of33health33patterns33are33limited33to33activity,33fluid33volum
e,33nutritio33n,33self33care,33and33sensory33perception.33Basic33human33needs33co
mprise33less33than33merely33health33patterns.3 3 Pathophysiologic33needs3 3 are33n
otspart33of33the33scope33of33NANDAI.
, DIF:33Cognitive33Level:33Knowledge33R
EF:33pp.3337-3833OBJ:33533TOP:
Nursing33Process33Step:33Diagnosis
MSC:33NCLEX33Client33Needs33Category:33Physiological33Integrity
• Which33task33is33included33in33the33assessment33step33of33the33nursing33process?
A. Establishings33patient33goals/outcomes
B. Implementing33the33nursing33care33plan33(NCP)
C. Measuring33goal/outcome33achievement
D. Collecting33ands33communicating33data
ANS:sD
Data33are33collected33andscommunicated33insthe33assessment33phase33of33thenurs
ings3 3 process.33Establishing33goals33issthe33functionsof33planning.
Implementing33the33NCP33is33the33function33of33implementation.33Measuringo3
3utcome33achievement33is33thesfunction33of33evaluation.
DIF:33Cognitive33Level:33Comprehensio
ns3 3 REF:33dm333633OBJ:33233|33333TOP:33N
ursing33Pr33ocess33Step:33Assessment
MSC:33NCLEX33Client33Needs33Category:33Health33Promotion33and33Maintenance
• Which33statement33regardings33nursing33diagnoses33is33accurate?
a. Nursing33diagnosessremain33the33same33forsasslongsas33the33disease33is33 present.
b. Nursing33diagnoses33are33written33to33identify33disease33states.
c. Nursing33diagnoses33describe33patient33problems33that33nurses33treat.
d. Nursing33diagnoses33identify33causes33related33to33illness.
ANS:33C
Diagnostic33statements33identify33problems33a33nurses33is33independently33able3
3tostre33at33within33the33scope33of33professional33practice.33Nursing33diagnoses33v
ary33with33the33changing33condition33of33the33patient.33The33response33patterns33
aresunique33to33the33pa33tient33and33aresnotsdisease33specific.33Nursingsdiagnose
s33describe33thespatients33hu33man33response33pattern.
DIF:33Cognitive33Level:33Comprehension